SecBot SecBot

AXSM drug pipeline

Axsome Therapeutics, Inc. · 4 rated drugs
$137.01
−3.3% 1-day · Nov 16
Next catalyst
May 1, 2027
AXS-12 PDUFA date · in 166 days
Typical move on FDA news
±8.0%
1-day, median of 19 events
IV rank
No data
No current options data
Rated drugs
4
1 bullish · 3 neutral
Phase 3 trials
3
2 with results posted

Upcoming catalysts

1 dated
  1. May 1, 2027166d
    AXS-12
    PDUFA date · cataplexy in narcolepsy

Drugs

soonest catalyst first
● neutral
Impact
PhaseFiled/PDUFA (NDA accepted; Phase 3 completed)
Time to marketNDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.

AXS-12 reboxetine Updated Aug 17

166days
Next catalyst
PDUFA date · May 1, 2027 · cataplexy in narcolepsy
What to watch

Watch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.

Bull case
  • NDA accepted and FDA set a PDUFA target action date of May 1, 2027, with no advisory committee meeting currently planned, less regulatory-uncertainty risk.
  • AXS-12 has FDA Orphan Drug designation for narcolepsy, which can bring 7-year US exclusivity if approved.
  • Completed Phase 3 (NCT05059223, ~90 patients) and Phase 2 CONCERT (NCT03881852) plus decades of prior human use as an antidepressant reduce the 'new mechanism safety surprise' risk.
Bear case
  • The PDUFA is ~8.5 months away (May 1, 2027), a distant binary with FDA refusal-to-file/CRL risk in between; the stock already ran up ~97.7% over 12 months.
  • Reboxetine is an old drug: it had generic competition and a mixed commercial/efficacy record as an antidepressant, so Axsome must differentiate it against entrenched narcolepsy treatments (e.g., oxybates, pitolisant) for a niche cataplexy population (context; not from web sources this session).
  • Insider selling: CEO Herriot Tabuteau sold ~$9.5M of stock on Aug 5, 2026 at $212.01 and ~$1.0M on Aug 6 at $213.95 (10b5-1 flagged).
▲ bullish
Impact
PhaseApproved (Phase 3 completed for Alzheimer's agitation; Phase 2/3 planned for smoking cessation)
Time to marketAlready on the market — originally approved for MDD in August 2022; new Alzheimer's agitation indication launched June 2026.

AXS-05 dextromethorphan hydrobromide / bupropion hydrochloride Updated Jul 9

What to watch

Auvelity's recent FDA approval for Alzheimer's agitation (April 30, 2026) opens a large new addressable market. Watch Q2 2026 and Q3 2026 earnings for early commercial traction in this new indication, revenue growth trajectory will determine whether the stock can sustain its ~155% 52-week rally. The Phase 2/3 smoking cessation trial starting Q2 2026 is a pipeline upside catalyst but likely >12 months from a readout.

Bull case
  • Auvelity is already generating substantial and rapidly growing revenue, $507.1M in FY2025 (74% YoY growth), $153.2M in Q1 2026 (59% YoY growth), proving commercial viability in MDD.
  • The FDA approval for Alzheimer's disease agitation (April 30, 2026) opens a huge new market: up to 76% of the 7M+ Alzheimer's patients in the U.S. experience agitation. Auvelity is the first non-antipsychotic approved for this indication, offering a potentially safer alternative to Rexulti (brexpiprazole).
  • Management raised Auvelity peak sales guidance to at least $8 billion (split ~50/50 between MDD and Alzheimer's agitation), a massive step up from prior expectations.
Bear case
  • The key binary catalyst (Alzheimer's agitation sNDA approval) has already passed. Without a new near-term regulatory decision, near-term stock movement depends on commercial execution, which is gradual rather than binary.
  • Auvelity carries a black-box warning for suicidal thoughts and behaviors, which is standard for antidepressants but could dampen adoption in elderly Alzheimer's patients who are already vulnerable.
  • Competition in Alzheimer's agitation includes Rexulti (Otsuka/Lundbeck), an already-approved antipsychotic, plus emerging pipeline drugs like Cobenfy (BMS/Karuna) and IGC-AD1 (IGC Pharma).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched (January 30, 2025)

AXS-07 meloxicam and rizatriptan Updated Jul 9

What to watch

AXS-07 is already approved and generating early revenue, so its binary risk is behind it. For an AXSM investor, watch SYMBRAVO prescription trends and payer access as leading indicators of commercial traction, but the bigger near-term stock drivers are AUVELITY's Alzheimer's agitation launch and pipeline catalysts for AXS-12/solriamfetol.

Bull case
  • SYMBRAVO fills a clear niche: patients who need faster-acting migraine relief than oral CGRP inhibitors (gepants) or who had inadequate response to triptans alone, the EMERGE trial specifically studied CGRP-inadequate responders.
  • The combination multi-mechanistic approach (NSAID + triptan) differentiates it from single-mechanism competitors; Phase 3 data showed pain freedom as early as 30 minutes post-dose.
  • Analyst consensus on AXSM is Strong Buy (25 buy/strong buy vs 2 hold) with a mean price target of $276.56, implying ~45% upside from recent levels. Top-tier firms (RBC, HC Wainwright, Needham, Mizuho) maintain Outperform/Buy ratings.
Bear case
  • SYMBRAVO is entering a crowded acute migraine market with entrenched generic triptans, established branded gepants (Pfizer/Biohaven's Nurtec with ~$1B+ annual sales, AbbVie's Ubrelvy), and Lilly's Reyvow, competing for payer coverage and mindshare will be expensive.
  • Early launch revenue of just $4.1M in Q1 2026 is modest relative to Axsome's $191M total revenue; SYMBRAVO is a small contributor and may never reach blockbuster status in this competitive field.
  • The drug has a complex regulatory history, a prior CRL in May 2022, and the approval came via a Class 2 resubmission, indicating CMC/manufacturing risks were only recently resolved.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (Sunosi, FDA-approved 2019)

solriamfetol Updated Jul 7

What to watch

Solriamfetol is a steady commercial contributor (~$125M FY2025, 32% YoY) with patent protection through 2040, but it is not Axsome's primary growth driver, Auvelity is larger (~$291M in 2024) and just won an Alzheimer's agitation approval. Watch for whether Axsome files an ADHD sNDA in 2H 2026 or 2027, which would create a new regulatory catalyst. Until then, solriamfetol's value is in its reliable cash flow and pipeline-expansion optionality.

Bull case
  • Sunosi revenue grew 32% YoY to $124.8M in FY2025 and continued accelerating to 34% growth in Q1 2026 ($33.9M), showing strong commercial execution under Axsome's ownership (source: investingnews.com/Q1 2026 earnings).
  • Patent settlements with five generic manufacturers block generic competition until 2040 (March or September), securing long-term cash flow from the approved indications (source: fiercepharma.com).
  • The FOCUS Phase 3 adult ADHD trial met its primary endpoint with a 45% reduction in ADHD symptoms, representing a potential large new indication for a drug with an established safety profile (source: technologynetworks.com).
Bear case
  • Solriamfetol is a small part of Axsome's overall story, just $124.8M of the company's $638.5M total FY2025 revenue, dwarfed by Auvelity (~$291M in 2024 plus new Alzheimer's agitation approval). Pipeline setbacks may be overlooked if investors focus on the bigger Auvelity/AXS-05 franchise (source: fiercepharma.com).
  • The PARADIGM Phase 3 trial in broad major depressive disorder failed its primary endpoint in April 2025, revealing limits to solriamfetol's utility as an antidepressant (source: benzinga.com).
  • No sNDA has been filed for adult ADHD despite positive FOCUS Phase 3 data in March 2025, the regulatory timeline remains unclear, and the company is instead focusing on lengthy pediatric trials that will take years to complete (source: biospace.com).

Past FDA events & how the stock moved

19 events
DateDrugEvent1 day5 days
Aug 10, 2026AXS-12NDA filed+1.4%+1.7%
Aug 10, 2026AXS-12Orphan drug designation+1.4%+1.7%
Jul 15, 2026AXS-12NDA filed+0.8%+1.9%
May 4, 2026AXS-12NDA filed+8.0%+4.8%
Apr 30, 2026AXS-12Orphan drug designation+12.3%+19.7%
Apr 30, 2026AXS-05PDUFA decision+12.3%+19.7%
Apr 30, 2026AXS-05Breakthrough designation+12.3%+19.7%
Apr 30, 2026AXS-05Priority review+12.3%+19.7%
Apr 30, 2026AXS-05Approval+12.3%+19.7%
Apr 1, 2026AXS-05Approval−0.3%+5.8%
Mar 31, 2026AXS-12NDA filed+7.0%+7.9%
Feb 23, 2026AXS-05Breakthrough designation−7.5%−9.4%
Feb 23, 2026AXS-05Priority review−7.5%−9.4%
Dec 31, 2025AXS-05NDA filed+20.1%+12.6%
Dec 31, 2025AXS-12Orphan drug designation+20.1%+12.6%
Dec 31, 2025AXS-05Priority review+20.1%+12.6%
Jan 30, 2025AXS-07Approval+1.3%+4.2%
Aug 18, 2022AXS-05Approval+38.1%+62.0%
Mar 20, 2019solriamfetolApproval+2.2%+12.8%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
AXS-05An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyPhase 3Terminated · results139Feb 17, 2025
AXS-05A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationPhase 3Completed · results408Nov 21, 2024
AXS-12A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyPhase 3Completed90Mar 15, 2024
AXS-12Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)Phase 2Completed · results21Nov 27, 2019